Large installed base Thirona's LungQ portfolio is installed in over 1,200 hospitals worldwide, indicating a broad potential audience for expanding upsell opportunities, cross-sell of related LungQ modules, and enterprise contracts with hospital networks.

Clinical trial focus The solution is used to accelerate imaging-based respiratory clinical trials, presenting a strong entry point for partnerships with CROs, pharma companies, and MedTech integrators seeking AI-driven imaging endpoints and standardized biomarkers.

AI lung phenotyping Recent LungQ developments such as AVX for artery-vein phenotyping and comprehensive airway characterization position Thirona to address granular anatomical biomarkers, enabling advanced discussions with academic medical centers and pharmaceutical researchers.

Strategic finance Funding history includes EU support and recent acquisitions, signaling investor validation and potential for strategic collaborations or co-development deals with larger health-tech groups or VCs looking to augment portfolio with AI-imaging capabilities.

Growth through partnerships Collaborations with research institutes, academic hospitals, pharmaceutical innovators, and MedTech partners suggest a propitious path for channel partnerships, system integrators, and data-sharing agreements to expand adoption and deployment.